BG
MRTX

Bellevue Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bellevue Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,800
Closed -$1.22M – 185
2022
Q1 		$1.22M Sell
14,800
-6,800
-31% -$695K 0.01% 142
2021
Q4 		$3.17M Buy
21,600
+2,700
+14% +$419K 0.03% 136
2021
Q3 		$3.34M Buy
18,900
+11,600
+159% +$1.87M 0.03% 138
2021
Q2 		$1.18M Sell
7,300
-2,500
-26% -$401K 0.01% 149
2021
Q1 		$1.68M Sell
9,800
-2,500
-20% -$495K 0.02% 147
2020
Q4 		$2.7M Sell
12,300
-5,500
-31% -$1.19M 0.03% 137
2020
Q3 		$2.96M Hold
17,800
– – 0.04% 136
2020
Q2 		$2.03M Buy
17,800
+1,900
+12% +$184K 0.03% 134
2020
Q1 		$1.22M Sell
15,900
-400
-2% -$35.9K 0.02% 139
2019
Q4 		$2.1M Buy
16,300
+400
+3% +$38.6K 0.03% 129
2019
Q3 		$1.24M Sell
15,900
-5,600
-26% -$526K 0.02% 135
2019
Q2 		$2.21M Buy
21,500
+7,000
+48% +$545K 0.04% 126
2019
Q1 		$1.06M Sell
14,500
-9,500
-40% -$646K 0.06% 126
2018
Q4 		$1.02M Sell
24,000
-1,000
-4% -$39.9K 0.07% 114
2018
Q3 		$1.18M Sell
25,000
-500
-2% -$27.8K 0.07% 123
2018
Q2 		$1.26M Buy
+25,500
New +$963K 0.11% 111

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bellevue Group's MRTX Position: Q2 2022 in Review

Bellevue Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 14,800 shares — an estimated $1.22M sold.

Bellevue Group first reported a position in MRTX in Q2 2018 and held it in 16 quarters. The position peaked at $3.34M in Q3 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

  • Bellevue Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bellevue Group sold 14,800 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1.22M.
  • Bellevue Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 16 quarters.
  • Bellevue Group's Mirati Therapeutics, Inc. Common Stock position peaked at $3.34M in Q3 2021.
  • 230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Bellevue Group's 13F filing for Q2 2022, filed 11 Aug 2022.